What Are Chinese Pharma CEOs Ranting About? (Part 1 of 2)
This article was originally published in PharmAsia News
Top pharma executives in China get a chance to air their rants during a once-a-year “meet the regulators” session in Beijing, while regulators including the CFDA deputy commissioner share candid views on pertinent industry issues such as the drug approval backlog, pricing, provincial tenders and the essential drug list.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.